ABSTRACT
"Greedy" and "Big Pharma". These terms just seem to fit together so naturally! Calling someone or some entity "Greedy" is at least unpleasant and at worst downright nasty. The American Association of Retired Persons (AARP) has been among the most vocal of those applying that appellation to Big Pharma. AARP argued in their Report that several options were available to limit or reduce Drug Prices. A 30-year-old retrospective look at how Congress saw things then is provided in the Majority Staff Report of the US Senate Special Committee on Aging. The Report then presented three options for Legislation "to mitigate the impact of rising drug prices". The three options included: a voluntary approach designed to assist States in arriving at scientifically and clinically valid assessments of Drug equivalency, a "flexible mandate" that encourages immediate State action in anticipation of an eventual Federal mandate, and a centralized, mandated Federal program.
